Disease-modifying antirheumatic drugs (DMARDs) are a class of drugs indicated for the treatment of several inflammatory arthritides, including rheumatoid arthritis (RA), as well as for the management of other connective tissue diseases and some cancers. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of DMARDs, pertinent for members of the interprofessional team in the treatment of patients with autoimmune disorders that will respond to such therapy.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
66% Article relates to my practice (2/3)
0% Article does not relate to my practice (0/3)
33% Undecided (1/3)
2

Will this article lead to more cost-effective healthcare?

33% Yes (1/3)
66% No (2/3)
0% Undecided (0/3)
3

Was this article biased? (commercial or personal)

33% Yes (1/3)
66% No (2/3)
0% Undecided (0/3)
4

What level of evidence do you think this article is?

0% Level 1 (0/3)
0% Level 2 (0/3)
66% Level 3 (2/3)
0% Level 4 (0/3)
33% Level 5 (1/3)